Find

Department of Clinical Medicine

Kristina Laut Matzen

Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Standard

Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study. / Andersen, Asger ; Matzen, Kristina Laut ; Andersen, Grethe et al.

I: Catheterization and Cardiovascular Interventions, Bind 99, Nr. 5, 04.2022, s. 1551-1557.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Harvard

Andersen, A , Matzen, KL , Andersen, G, Settergren, M, Sjostrand, C, Iversen, HK, Roine, RO, Hildick-Smith, D, Spence, JD, Rhodes, JF, Kasner, SE, Sondergaard, L & Nielsen-Kudsk, JE 2022, 'Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study', Catheterization and Cardiovascular Interventions, bind 99, nr. 5, s. 1551-1557. https://doi.org/10.1002/ccd.30019

APA

Andersen, A., Matzen, K. L., Andersen, G., Settergren, M., Sjostrand, C., Iversen, H. K., Roine, R. O., Hildick-Smith, D., Spence, J. D., Rhodes, J. F., Kasner, S. E., Sondergaard, L., & Nielsen-Kudsk, J. E. (2022). Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study. Catheterization and Cardiovascular Interventions, 99(5), 1551-1557. https://doi.org/10.1002/ccd.30019

CBE

Andersen A , Matzen KL , Andersen G, Settergren M, Sjostrand C, Iversen HK, Roine RO, Hildick-Smith D, Spence JD, Rhodes JF, et al. 2022. Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study. Catheterization and Cardiovascular Interventions. 99(5):1551-1557. https://doi.org/10.1002/ccd.30019

MLA

Andersen, Asger et al. "Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study". Catheterization and Cardiovascular Interventions. 2022, 99(5). 1551-1557. https://doi.org/10.1002/ccd.30019

Vancouver

Andersen A , Matzen KL , Andersen G, Settergren M, Sjostrand C, Iversen HK et al. Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study. Catheterization and Cardiovascular Interventions. 2022 apr.;99(5):1551-1557. doi: 10.1002/ccd.30019

Author

Andersen, Asger ; Matzen, Kristina Laut ; Andersen, Grethe et al. / Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study. I: Catheterization and Cardiovascular Interventions. 2022 ; Bind 99, Nr. 5. s. 1551-1557.

Bibtex

@article{5f126f8f50194ffca612a7c408191ea4,

title = "Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study",

abstract = "OBJECTIVES: To describe the occurrence of postprocedural atrial fibrillation (AF) among patients with cryptogenic stroke undergoing patent foramen ovale (PFO) closure in the REDUCE clinical study and analyze for potential risk factors for the development of postprocedural AF.BACKGROUND: AF is an adverse event that might potentially counterbalance the stroke prevention benefit from PFO closure. Data on AF after transcatheter PFO closure are sparse.METHODS: We evaluated data from patients having PFO closure (Gore HELEX or Gore Cardioform Septal Occluder) in the REDUCE clinical trial (n = 408) in at post hoc explorative analysis. Median follow-up was 5.0 years.RESULTS: AF occurred in 30 patients (7.4%) after PFO closure with a total of 34 AF events. Most were reported as non-serious (68%), detected within 45 days post-procedure (79%), and resolved within 2 weeks of onset (63%). One subject with AF had recurrent stroke. Postprocedural AF occurred more frequently among subjects with higher age and large device sizes. Male sex was the only independent predictor of postprocedural AF. We found no association between the type of occluder (HELEX or Gore Cardioform Septal Occluder) or PFO anatomical characteristics and post-procedural AF.CONCLUSION: In the REDUCE clinical study, postprocedural atrial fibrillation was mostly early onset, transient and with no later recurrence. Postprocedural AF occurred more frequently among patients with higher age and larger devices. Male sex was the only independent predictor of postprocedural AF.",

keywords = "atrial fibrillation, patent foramen ovale, percutaneous closure, stroke",

author = "Asger Andersen and Matzen, {Kristina Laut} and Grethe Andersen and Magnus Settergren and Christina Sjostrand and Iversen, {Helle K} and Roine, {Risto O} and David Hildick-Smith and Spence, {John David} and Rhodes, {John F} and Kasner, {Scott E} and Lars Sondergaard and Nielsen-Kudsk, {Jens Erik}",

note = "{\textcopyright} 2021 Wiley Periodicals LLC.",

year = "2022",

month = apr,

doi = "10.1002/ccd.30019",

language = "English",

volume = "99",

pages = "1551--1557",

journal = "Catheterization and Cardiovascular Interventions",

issn = "1522-1946",

publisher = "JohnWiley & Sons, Inc.",

number = "5",

}

RIS

TY - JOUR

T1 - Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study

AU - Andersen, Asger

AU - Matzen, Kristina Laut

AU - Andersen, Grethe

AU - Settergren, Magnus

AU - Sjostrand, Christina

AU - Iversen, Helle K

AU - Roine, Risto O

AU - Hildick-Smith, David

AU - Spence, John David

AU - Rhodes, John F

AU - Kasner, Scott E

AU - Sondergaard, Lars

AU - Nielsen-Kudsk, Jens Erik

PY - 2022/4

Y1 - 2022/4

N2 - OBJECTIVES: To describe the occurrence of postprocedural atrial fibrillation (AF) among patients with cryptogenic stroke undergoing patent foramen ovale (PFO) closure in the REDUCE clinical study and analyze for potential risk factors for the development of postprocedural AF.BACKGROUND: AF is an adverse event that might potentially counterbalance the stroke prevention benefit from PFO closure. Data on AF after transcatheter PFO closure are sparse.METHODS: We evaluated data from patients having PFO closure (Gore HELEX or Gore Cardioform Septal Occluder) in the REDUCE clinical trial (n = 408) in at post hoc explorative analysis. Median follow-up was 5.0 years.RESULTS: AF occurred in 30 patients (7.4%) after PFO closure with a total of 34 AF events. Most were reported as non-serious (68%), detected within 45 days post-procedure (79%), and resolved within 2 weeks of onset (63%). One subject with AF had recurrent stroke. Postprocedural AF occurred more frequently among subjects with higher age and large device sizes. Male sex was the only independent predictor of postprocedural AF. We found no association between the type of occluder (HELEX or Gore Cardioform Septal Occluder) or PFO anatomical characteristics and post-procedural AF.CONCLUSION: In the REDUCE clinical study, postprocedural atrial fibrillation was mostly early onset, transient and with no later recurrence. Postprocedural AF occurred more frequently among patients with higher age and larger devices. Male sex was the only independent predictor of postprocedural AF.

AB - OBJECTIVES: To describe the occurrence of postprocedural atrial fibrillation (AF) among patients with cryptogenic stroke undergoing patent foramen ovale (PFO) closure in the REDUCE clinical study and analyze for potential risk factors for the development of postprocedural AF.BACKGROUND: AF is an adverse event that might potentially counterbalance the stroke prevention benefit from PFO closure. Data on AF after transcatheter PFO closure are sparse.METHODS: We evaluated data from patients having PFO closure (Gore HELEX or Gore Cardioform Septal Occluder) in the REDUCE clinical trial (n = 408) in at post hoc explorative analysis. Median follow-up was 5.0 years.RESULTS: AF occurred in 30 patients (7.4%) after PFO closure with a total of 34 AF events. Most were reported as non-serious (68%), detected within 45 days post-procedure (79%), and resolved within 2 weeks of onset (63%). One subject with AF had recurrent stroke. Postprocedural AF occurred more frequently among subjects with higher age and large device sizes. Male sex was the only independent predictor of postprocedural AF. We found no association between the type of occluder (HELEX or Gore Cardioform Septal Occluder) or PFO anatomical characteristics and post-procedural AF.CONCLUSION: In the REDUCE clinical study, postprocedural atrial fibrillation was mostly early onset, transient and with no later recurrence. Postprocedural AF occurred more frequently among patients with higher age and larger devices. Male sex was the only independent predictor of postprocedural AF.

KW - atrial fibrillation

KW - patent foramen ovale

KW - percutaneous closure

KW - stroke

U2 - 10.1002/ccd.30019

DO - 10.1002/ccd.30019

M3 - Journal article

C2 - 34773685

VL - 99

SP - 1551

EP - 1557

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 5

ER -